Registry of patients with pulmonary hypertension receiving targeted therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CHASE Registry aims to collect and analyze clinical characteristics and treatment strategies of patients with pulmonary hypertension in China who are receiving targeted therapies. This multicenter, prospective observational study will enroll at least 5000 patients, who will be followed for three years with assessments every six months. The study focuses on real-world data to understand disease progression, treatment outcomes, and the effectiveness of targeted drugs in managing pulmonary hypertension.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Sign informed consent;
* Between the ages of 18 and 85;
* Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).

Exclusion Criteria:

* Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
* Patients with malignant tumor and other diseases and life expectancy of less than half a year;
* Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension

Where it's running

• Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC
  Beijing, China Recruiting

Study contacts

• Principal investigator: Zhihong Liu, M.D., Ph.D — Chinese Academy of Medical Sciences, Fuwai Hospital
• Study coordinator: Zhihong Liu, M.D., Ph.D
• Email: zhihongliufuwai@163.com
• Phone: 8601088396816

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER

  This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.

  Recruiting Early Phase 1 Xiamen Cardiovascular Hospital, Xiamen University · Xiamen, Fujian · NCT07662655

• Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

  This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.

  Recruiting at 4 sites Peking Union Medical College Hospital · Guangzhou, Guangdong and 3 other locations · NCT07653958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.